343 related articles for article (PubMed ID: 35105687)
1. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
Zabalza A; Arrambide G; Tagliani P; Cárdenas-Robledo S; Otero-Romero S; Esperalba J; Fernandez-Naval C; Trocoli Campuzano J; Martínez Gallo M; Castillo M; Bonastre M; Resina Sallés M; Beltran J; Carbonell-Mirabent P; Rodríguez-Barranco M; López-Maza S; Melgarejo Otálora PJ; Ruiz-Ortiz M; Pappolla A; Rodríguez Acevedo B; Midaglia L; Vidal-Jordana A; Cobo-Calvo A; Tur C; Galán I; Castilló J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105687
[TBL] [Abstract][Full Text] [Related]
2. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
3. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
4. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
6. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
Habek M; Jakob Brecl G; Bašić Kes V; Rogić D; Barun B; Gabelić T; Emeršič A; Horvat Ledinek A; Grbić N; Lapić I; Šegulja D; Đurić K; Adamec I; Krbot Skorić M
J Neuroimmunol; 2021 Oct; 359():577696. PubMed ID: 34418815
[TBL] [Abstract][Full Text] [Related]
8. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
[TBL] [Abstract][Full Text] [Related]
9. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
Adamec I; Rogić D; Penz MG; Braun C; Habek M
J Neuroimmunol; 2022 Jan; 362():577788. PubMed ID: 34922128
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Bsteh G; Dürauer S; Assar H; Hegen H; Heschl B; Leutmezer F; Pauli FD; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Höftberger R; Enzinger C; Berger T
Mult Scler; 2021 Dec; 27(14):2209-2218. PubMed ID: 34595968
[TBL] [Abstract][Full Text] [Related]
12. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study.
Krajnc N; Hegen H; Traxler G; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Riedl K; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T; Bsteh G
Mult Scler Relat Disord; 2022 Sep; 65():104009. PubMed ID: 35797803
[TBL] [Abstract][Full Text] [Related]
14. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
Bigaut K; Kremer L; Fabacher T; Lanotte L; Fleury MC; Collongues N; de Seze J
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34321333
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies.
Habek M; Željko C; Savić Mlakar A; Bendelja K; Rogić D; Adamec I; Barun B; Gabelić T; Krbot Skorić M
Mult Scler Relat Disord; 2022 Mar; 59():103682. PubMed ID: 35158189
[TBL] [Abstract][Full Text] [Related]
16. Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I; Patskovsky Y; Curtin R; Pei J; Perdomo K; Rimler Z; Voloshyna I; Samanovic MI; Cornelius AR; Velmurugu Y; Nyovanie S; Kim JJ; Tardio E; Bacon TE; Zhovtis Ryerson L; Raut P; Pedotti R; Hawker K; Raposo C; Priest J; Cabatingan M; Winger RC; Mulligan MJ; Krogsgaard M; Silverman GJ
Ann Neurol; 2022 Jun; 91(6):782-795. PubMed ID: 35289960
[TBL] [Abstract][Full Text] [Related]
17. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
Wu X; Wang L; Shen L; Tang K
EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
[TBL] [Abstract][Full Text] [Related]
18. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
König M; Lorentzen ÅR; Torgauten HM; Tran TT; Schikora-Rustad S; Vaage EB; Mygland Å; Wergeland S; Aarseth J; Aaberge IAS; Torkildsen Ø; Holmøy T; Berge T; Myhr KM; Harbo HF; Andersen JT; Munthe LA; Søraas A; Celius EG; Vaage JT; Lund-Johansen F; Nygaard GO
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):19-22. PubMed ID: 34670844
[TBL] [Abstract][Full Text] [Related]
20. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Zabalza A; Arrambide G; Otero-Romero S; Pappolla A; Tagliani P; López-Maza S; Cárdenas-Robledo S; Esperalba J; Fernández-Naval C; Martínez-Gallo M; Castillo M; Bonastre M; Resina-Salles M; Bertran J; Rodriguez-Barranco M; Carbonell-Mirabent P; Gonzalez M; Merchan M; Quiroga-Varela A; Miguela A; Gómez I; Álvarez G; Robles R; Perez Del Campo D; Queralt X; Soler MJ; Agraz I; Martinez-Valle F; Rodríguez-Acevedo B; Midaglia L; Vidal-Jordana Á; Cobo-Calvo Á; Tur C; Galan I; Castillo J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Ramió-Torrentà L; Tintoré M; Montalban X
Mult Scler; 2022 Jun; 28(7):1138-1145. PubMed ID: 35475363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
